StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research note on Wednesday, August 7th.
Get Our Latest Stock Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Up 5.6 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). On average, sell-side analysts anticipate that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Recommended Stories
- Five stocks we like better than Minerva Neurosciences
- Top Stocks Investing in 5G Technology
- Why Block’s Key Components Make It a Solid Investment Choice
- Investing in Commodities: What Are They? How to Invest in Them
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Ride Out The Recession With These Dividend KingsĀ
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.